View Future GrowthAnGes 과거 순이익 실적과거 기준 점검 0/6AnGes 의 수입은 연평균 -19.9%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 32.2%의 비율로 증가해 왔습니다.핵심 정보-19.95%순이익 성장률-7.44%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률32.15%자기자본이익률-1,304.64%순이익률-4,374.49%다음 순이익 업데이트09 May 2025최근 과거 실적 업데이트공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025모든 업데이트 보기Recent updates공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026공시 • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.공시 • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026공시 • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025공시 • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025공시 • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024공시 • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024공시 • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024공시 • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.공시 • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.공시 • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.공시 • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024공시 • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.공시 • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.공시 • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.공시 • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023공시 • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023매출 및 비용 세부 내역AnGes가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:AMGX.F 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Dec 24643-28,1285,5743,78330 Sep 24521-9,7952,4304,26130 Jun 24448-6,1072,7415,25331 Mar 24249-6,3502,6405,56431 Dec 23152-7,4372,5116,17230 Sep 23124-9,3182,5857,31130 Jun 2387-12,1192,3827,54631 Mar 2368-14,6872,27710,31131 Dec 2267-14,7142,10410,99930 Sep 2265-11,9172,41110,82030 Jun 2272-13,6502,10212,43931 Mar 2268-13,2992,24810,63431 Dec 2164-13,6752,18910,78330 Sep 2155-12,9874,25910,40630 Jun 2146-9,7633,4917,65331 Mar 2145-6,6042,4395,58431 Dec 2039-4,2091,5713,79630 Sep 2031-4,1541,1642,50830 Jun 20170-3,6731,1852,18931 Mar 20255-3,4851,2682,84331 Dec 19326-3,7501,1842,21530 Sep 19656-3,5641,1602,87930 Jun 19605-3,8221,0593,26831 Mar 19612-3,6439222,53931 Dec 18610-2,9968832,53930 Sep 18387-2,6079021,66530 Jun 18373-2,6129551,61031 Mar 18356-2,7908831,72531 Dec 17365-3,7648612,60030 Sep 17513-4,3127973,17830 Jun 17514-4,2507273,17031 Mar 17514-5,0577704,07231 Dec 16514-4,7768004,18830 Sep 16366-4,9599444,14030 Jun 16359-4,9289054,23131 Mar 16432-4,4908693,76331 Dec 15430-4,1438823,53230 Sep 15948-3,2868083,21330 Jun 15975-3,4418093,23231 Mar 15908-2,8147622,73831 Dec 14909-2,3696872,33830 Sep 14381-2,5286732,01330 Jun 14351-1,7256451,31531 Mar 14448-1,4816571,156양질의 수익: AMGX.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: AMGX.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: AMGX.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 19.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 AMGX.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: AMGX.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: AMGX.F는 현재 수익성이 없으므로 자본 수익률이 음수(-1304.64%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/03/04 03:02종가2024/12/05 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AnGes, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.Shinichiro MuraokaMorgan Stanley
공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026
공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025
공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025
공시 • May 08AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026
공시 • Mar 26Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis PatientsVasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
공시 • Feb 10AnGes, Inc., Annual General Meeting, Mar 27, 2026AnGes, Inc., Annual General Meeting, Mar 27, 2026.
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026
공시 • Sep 04Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis PatientsA groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population.
공시 • Sep 01AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025
공시 • May 31AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025
공시 • Mar 01AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025
공시 • Feb 14AnGes, Inc., Annual General Meeting, Mar 28, 2025AnGes, Inc., Annual General Meeting, Mar 28, 2025.
공시 • Dec 03AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025
공시 • Aug 27AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024
공시 • Jun 02AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024
공시 • Mar 23AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024
공시 • Mar 20AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald EuropeAnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe.
공시 • Feb 11AnGes, Inc., Annual General Meeting, Mar 28, 2024AnGes, Inc., Annual General Meeting, Mar 28, 2024.
공시 • Jan 19Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanEiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS.
공시 • Dec 05AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024
공시 • Nov 15Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a StudyVasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival.
공시 • Jul 13AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd.On July 12, 2023, AnGes, Inc. closed the transaction.
공시 • Jun 27AnGes, Inc. announced that it expects to receive ¥8.481467 million in fundingAnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023.
공시 • May 28AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023
공시 • Dec 28AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023